Quality & complianceOfficial

Teva's Bendroza 2.5+573 mg tablets face Danish supply problems into January 2027

🇩🇰 DKMA · Wed 04 Nov 2026

The Danish Medicines Agency says Teva Denmark's bendroflumethiazide and potassium chloride tablets are affected by increased demand, with only a partial delivery of 100 packs expected in early October.

The Danish Medicines Agency (DKMA) has published a supply notice for Bendroza 2.5+573 mg film-coated tablets from Teva Denmark A/S. The notice first appeared on 29 September 2026 and was updated on 4 November 2026.

The product contains bendroflumethiazide and potassium chloride and carries the ATC code C03AB01. DKMA gives the expected period of supply difficulty as late August 2026 to early January 2027.

The agency attributes the problem to increased sales and demand. As additional information, it notes a partial delivery of 100 units in early October. The notice does not say whether further deliveries are planned, and it names no alternative products.

DKMA directs questions about the current status to the company. The notice sits among the agency's published supply announcements for human medicines.

What it means for your team

  • Supply and market-access teams in Denmark should check Bendroza stock against the stated shortage window, which runs to early January 2027.
  • The notice names no alternatives and no cause beyond higher demand, so teams will need to approach Teva Denmark directly for current status.
  • Regulatory affairs teams handling shortage procedures should note that DKMA refers status questions to the marketing company rather than to the agency.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →